AI-generated analysis. Always verify with the original filing.
Lisata Therapeutics entered into a Merger Agreement with Kuva Labs Inc. and its subsidiary Kuva Acquisition Corp. for a tender offer to acquire all common shares at $5.00 per share in cash plus one non-tradeable CVR for a potential $1.00 milestone payment tied to certepetide regulatory filing. The Company Board unanimously approved and recommends stockholders tender their shares.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On March 6, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the “Company” or “
, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 2.1 * Agreement and Plan of Merger, dated as of March 6, 2026, among the Company, Parent
Material Agreement